.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Management of Chronic Lymphocytic Leukemia in 2020

EP. 1: Prognostic Factors in Patients With CLL

January 28th 2020

EP. 2: Mutation Status Throughout the CLL Clinical Course

January 28th 2020

EP. 3: Chemoimmunotherapy for CLL; Still a Role?

January 28th 2020

EP. 4: Long-Term Experience With BTK Inhibitors for CLL

January 28th 2020

EP. 5: Acalabrutinib, Second-Generation BTK Inhibitor for CLL

January 28th 2020

EP. 6: The Role of Venetoclax + Rituximab in CLL

January 28th 2020

EP. 7: Treatment for Younger Fit Patients With CLL

January 28th 2020

EP. 8: Ibrutinib + Venetoclax for CLL

January 28th 2020

EP. 9: Combining Targeted Therapies in CLL

January 28th 2020

EP. 10: Distinguishing Features Among BTK Inhibitors

January 28th 2020

EP. 11: Health Maintenance in CLL

January 28th 2020

EP. 12: Fixed-Duration Therapy for Relapsed CLL

January 28th 2020

EP. 13: Combinations for Relapsed or Refractory CLL

January 28th 2020

EP. 14: Resistance to Therapy in CLL

January 28th 2020

EP. 15: Management of CLL Progression After Ibrutinib

January 28th 2020

EP. 16: PI3 Kinase Inhibitors for Relapsed/Refractory CLL

January 28th 2020

EP. 17: Sequencing Strategies for CLL

January 28th 2020

EP. 18: CAR T-Cell Therapy for Relapsed/Refractory CLL

January 28th 2020

EP. 19: 2019 ASH; Best Abstracts for CLL

January 28th 2020